Association between psoriatic disease and dyslipidaemia: a chart-based observational study in the United Arab Emirates

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Psoriatic disease and dyslipidaemia (n=465). Intervention: Psoriatic disease (cutaneous psoriatic disease or psoriatic arthritis) vs. Patients without documented psoriatic disease or psoriatic arthritis. Primary outcome: Presence of dyslipidaemia (defined by predefined thresholds for triglycerides, total cholesterol, LDL-C, non-HDL-C, or sex-specific HDL-C) (aOR 1.37, 95% CI 0.88 to 2.16, p=0.200).

Q: What does this research mean for the field?

Psoriatic disease is associated with higher crude prevalence of dyslipidaemia, but this association is attenuated and not statistically significant overall after adjustment for age, BMI, and other covariates. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Khulood Abdulraouf Almarzooqi; Noura Almarzooqi; Amal Alghefari; Nouf Alnaqeeb; Sana Jasem AlShehhi; Aminu S. Abdullahi; Rami H. Al‐Rifai

doi:10.1136/bmjopen-2026-122453

November 1, 2026BMJ OpenOpen Access

Association between psoriatic disease and dyslipidaemia: a chart-based observational study in the United Arab Emirates

View Full Paper

Ask AI

Bookmark

Share

Key result

Psoriatic disease was associated with higher crude dyslipidaemia prevalence, but not independently after multivariable adjustment.

Figures

Why the study?

This study sought to examine the association between psoriatic disease and dyslipidaemia in a tertiary hospital setting in the United Arab Emirates.

Is psoriatic disease independently associated with higher odds of dyslipidaemia among patients undergoing lipid testing at a tertiary hospital in the United Arab Emirates?

Key Points

To examine the association between psoriatic disease and dyslipidaemia in a tertiary hospital setting in the United Arab Emirates.
Conducted a chart-based observational study of 465 eligible patients aged ≥16 years who underwent lipid testing at a tertiary care centre in Abu Dhabi between 2019 and 2023.
Classified dyslipidaemia using standard thresholds for triglycerides, total cholesterol, LDL, non-HDL, and HDL cholesterol, excluding individuals with inherited lipid disorders or lipid-altering medications.
Dyslipidaemia was present in 56.0% of patients with psoriatic disease compared with 44.9% of those without (p=0.038; crude OR 1.56, 95% CI 1.03 to 2.40).
Adjustment for age, BMI, and other covariates attenuated the association to statistical insignificance (aOR 1.37, 95% CI 0.88 to 2.16), while age ≥40 years and obesity remained independently associated.
Sex-stratified analysis revealed an independent association between psoriatic disease and dyslipidaemia in men (aOR 2.05, 95% CI 1.08 to 3.99), but no significant association was observed in women.

Study Design

Type

Observational (n=465)

Multicenter

No

Structured PICO

Is psoriatic disease independently associated with higher odds of dyslipidaemia among patients undergoing lipid testing at a tertiary hospital in the United Arab Emirates?

P

Population

465 patients aged >=16 years (median age 39 years, 55.9% female) attending dermatology or rheumatology outpatient clinics at a tertiary care hospital in the United Arab Emirates between 2019 and 2023 who underwent lipid testing, excluding those on lipid-altering medications or with inherited lipid disorders.

E

Exposure

Documented psoriatic disease (cutaneous psoriatic disease or psoriatic arthritis, n=116 [25.3%])

C

Comparator

Eligible patients without any documented psoriatic disease or psoriatic arthritis (n=343 [74.7%])

O

Outcome

Presence of dyslipidaemia on the index lipid profile, defined as meeting at least one threshold: triglycerides >=1.7 mmol/L (150 mg/dL), total cholesterol >=5.2 mmol/L (200 mg/dL), LDL-C >=3.4 mmol/L (130 mg/dL), non-HDL-C >=3.9 mmol/L (150 mg/dL), or HDL-C <=1.0 mmol/L (40 mg/dL) in men and <=1.3 mmol/L (50 mg/dL) in womensurrogate

Main Result

Odds Ratio: 1.37 (95% CI 0.88–2.16)

Absolute Event Rate: 56% vs 44.9%

p-value: p=0.200

In a UAE tertiary care cohort, higher crude rates of dyslipidaemia in patients with psoriatic disease were largely explained by age and BMI rather than psoriatic disease itself in the overall population, although an exploratory independent association was observed among men.

Limitations

Observational chart-based design precludes causal interpretation and is subject to residual confounding and uncertainty in temporal sequence.
Hospital-based specialty clinic sample restricted to lipid-tested patients limits generalisability and may introduce selection bias toward higher cardiometabolic risk.
Routine clinical lipid measurements rather than standardised research assays may have introduced measurement variability.
Planned sample size of 532 was not achieved (n=465), reducing statistical power particularly in sex-stratified subgroup analyses.
Standardised measures of psoriatic disease severity (e.g., PASI) were insufficiently documented to assess dose-response relationships.
Observational medical-record review design cannot establish causality or exact biological onset and temporal sequence of psoriatic disease and dyslipidaemia
Single-centre hospital-based population restricted to patients undergoing lipid testing in specialty clinics introduces potential selection bias and limits generalisability
Use of routine clinical care lipid measurements may introduce measurement variability
Insufficient documentation of standardised disease severity scores (such as PASI) precluded dose-response analysis
Target sample size of 532 was not reached (n=465 included), reducing statistical power and precision especially in sex-stratified subgroup analyses

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Age and BMI largely explain dyslipidaemia differences in psoriatic disease; leaves open independent risk in men for targeted studies.

Abstract

Objectives To examine the association between psoriatic disease and dyslipidaemia in a tertiary hospital setting in the United Arab Emirates. Design Chart-based observational study. Setting A tertiary hospital in the Emirate of Abu Dhabi, United Arab Emirates. Participants Patients aged ≥16 years who underwent lipid testing at a tertiary care centre in Abu Dhabi between 2019 and 2023 were included, regardless of their dyslipidaemia and psoriatic disease status. Primary and secondary outcome measures Dyslipidaemia was classified as present or absent using predefined thresholds for triglycerides, total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein (HDL) cholesterol and sex-specific HDL cholesterol. Among patients with psoriatic disease with dyslipidaemia, the first documented dyslipidaemia identification had to have occurred concurrently or after the recorded onset of psoriatic disease. Those with inherited lipid disorders or taking lipid-altering medications were excluded. Results The median age of the 465 eligible patients was 39 years (IQR 29–52 years) and 56% were women. Overall, 47.7% had dyslipidaemia and 25.3% had psoriatic disease. Dyslipidaemia was more common in patients with psoriatic disease than in those without (56.0% vs 44.9%; p=0.038). Unadjusted analysis revealed that psoriatic disease was associated with higher odds of dyslipidaemia (crude OR 1.56; 95% CI 1.03 to 2.40). After adjusting for age, body mass index (BMI) and other covariates, this association weakened and was no longer statistically significant (adjusted OR (aOR) 1.37; 95% CI 0.88 to 2.16). Age ≥40 years, overweight and obesity remained independently associated with dyslipidaemia. Sex-stratified analyses revealed that psoriatic disease was significantly independently associated with dyslipidaemia in men (aOR 2.05; 95% CI 1.08 to 3.99) but not in women. Conclusions In this hospital-based population, the crude prevalence of dyslipidaemia was higher among patients with psoriatic disease; however, this association was attenuated after adjusting for age, BMI and other covariates. An association persisted among men in the sex-stratified analysis. This should be interpreted cautiously, rather than as definitive evidence that sex modifies the association between psoriatic disease and dyslipidaemia. This observed association should be confirmed in larger studies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Almarzooqi et al. (2026) conducted an observational in Psoriatic disease and dyslipidaemia (n=465). Psoriatic disease (cutaneous psoriatic disease or psoriatic arthritis) vs. Patients without documented psoriatic disease or psoriatic arthritis was evaluated on Presence of dyslipidaemia (defined by predefined thresholds for triglycerides, total cholesterol, LDL-C, non-HDL-C, or sex-specific HDL-C) (aOR 1.37, 95% CI 0.88 to 2.16, p=0.200). Psoriatic disease was associated with higher crude dyslipidaemia prevalence, but not independently after multivariable adjustment.

synapsesocial.com/papers/6af73ac79badce7b6084da03 https://doi.org/10.1136/bmjopen-2026-122453

View Full Paper

Ask AI

Bookmark

Share

Association between psoriatic disease and dyslipidaemia: a chart-based observational study in the United Arab Emirates

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Association between psoriatic disease and dyslipidaemia: a chart-based observational study in the United Arab Emirates

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading